S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
NYSE:BHVN

Biohaven (BHVN) Stock Price, News & Analysis

$53.55
+2.49 (+4.88%)
(As of 04/11/2024 ET)
Today's Range
$51.20
$53.80
50-Day Range
$44.81
$59.74
52-Week Range
$12.35
$62.21
Volume
697,913 shs
Average Volume
1.15 million shs
Market Capitalization
$4.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.00

Biohaven MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2.9% Downside
$52.00 Price Target
Short Interest
Bearish
10.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Biohaven in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.85) to ($5.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.06 out of 5 stars

Medical Sector

2446th out of 2,796 stocks

Pharmaceutical Preparations Industry

1063rd out of 1,203 stocks

BHVN stock logo

About Biohaven Stock (NYSE:BHVN)

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

BHVN Stock Price History

BHVN Stock News Headlines

Think AI Is Big? Then You Should See This…
If you think AI is big, then you have got check out something we call Imperium…  Elon Musk calls it “amazing.” Bill Gates says Imperium is “one of the most powerful technologies of the 21st century.” And we expect it to grow 320,000% within three years.
BHVN Apr 2024 80.000 call
BHVN Oct 2024 90.000 call
BHVN May 2024 70.000 call
Think AI Is Big? Then You Should See This…
If you think AI is big, then you have got check out something we call Imperium…  Elon Musk calls it “amazing.” Bill Gates says Imperium is “one of the most powerful technologies of the 21st century.” And we expect it to grow 320,000% within three years.
BHVN Apr 2024 45.000 put
BHVN Oct 2024 30.000 call
Biohaven price target raised by $20 at TD Cowen, here's why
Biohaven Ltd BHVN
BHVN Mar 2024 30.000 put
BHVN Mar 2024 50.000 call
BHVN Oct 2024 70.000 call
A Look At The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/11/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
239
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.00
High Stock Price Target
$63.00
Low Stock Price Target
$28.00
Potential Upside/Downside
-2.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-408,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
$5.34 per share

Miscellaneous

Free Float
68,541,000
Market Cap
$4.37 billion
Optionable
Optionable
Beta
1.18
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

BHVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven's stock price target for 2024?

8 Wall Street analysts have issued 12 month price targets for Biohaven's shares. Their BHVN share price targets range from $28.00 to $63.00. On average, they predict the company's stock price to reach $52.00 in the next twelve months. This suggests that the stock has a possible downside of 2.9%.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2024?

Biohaven's stock was trading at $42.80 at the start of the year. Since then, BHVN stock has increased by 25.1% and is now trading at $53.55.
View the best growth stocks for 2024 here
.

Are investors shorting Biohaven?

Biohaven saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 7,730,000 shares, an increase of 21.0% from the February 14th total of 6,390,000 shares. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is currently 6.8 days.
View Biohaven's Short Interest
.

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BHVN earnings forecast
.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.41) by $0.40.

What ETFs hold Biohaven's stock?

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven IPO?

Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BHVN) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners